Filing Flows › Enanta Pharmaceuticals (ENTA) › Q3 FY26 › vs Q3 FY25
Enanta Pharmaceuticals (ENTA) Q3 FY26 vs Q3 FY25 (year over year)
Enanta Pharmaceuticals's revenue fell $4.0M (-22%) from $18.3M in Q3 FY25 to $14.4M in Q3 FY26.
Enanta Pharmaceuticals, Q3 FY26: revenue $14.4M (-22% year over year), operating margin -120.0%, net loss $19.5M, operating cash flow −$10.0M. The chart draws each line against Q3 FY25, the increases inside each band.
Every line
| Line | Q3 FY26 | Q3 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $14.4M | $18.3M | −$4.0M | -22% |
| Net loss | $19.5M | $18.3M | $1.2M | +7% |
| Costs & expenses | $33.9M | $37.2M | −$3.4M | -9% |
| Operating costs | $31.6M | $37.2M | −$5.6M | -15% |
| Interest & other, net | $2.2M | −$667K | $2.9M | — |
| Income tax | $36K | $29K | $7K | +24% |
| Research & development | $22.1M | $27.2M | −$5.1M | -19% |
| General & admin | $9.5M | $10.0M | −$528K | -5% |
| Operating cash sources | $19.5M | $18.3M | $1.2M | +7% |
| Depreciation & amortization | $1.2M | $1.2M | −$25K | -2% |
| Share-based compensation | $3.7M | $4.2M | −$494K | -12% |
| Working capital & other | $4.7M | $30.4M | −$25.7M | -85% |
| Cash used in operations | $10.0M | −$17.5M | $27.5M | — |
| Net loss absorbed | $19.5M | $18.3M | $1.2M | +7% |
Questions
How much did Enanta Pharmaceuticals's revenue grow year over year in Q3 FY26?
Enanta Pharmaceuticals's revenue fell $4.0M (-22%) from $18.3M in Q3 FY25 to $14.4M in Q3 FY26.